Kaisheng used to work in the University of Wisconsin, Amgen and Demera Pharmaceuticals. He has made outstanding achievements in the fields of biological drug research and development, production, quality control, and regulatory filings. He has led or participated in the IND or BLA application work for more than ten new drugs.

Kaisheng Huang joined RemeGen in 2019 and he is in charge of the RemeGen's GMP quality system and CMC compliance, committed to promoting the internationalization of domestic biologics as the CMC leader of Telitacicept. Kaisheng Huang received his PhD degree in medicinal chemistry from Peking Union Medical College and completed his post-doctoral research at the Institute of Biochemistry at Washington State University.